Genetic test is first to predict sensitivity of colon cancer metastases to radiation therapy

Scientists have developed the first test that analyzes the sensitivity of tumors to radiation therapy. They discovered that colon cancer metastases have varying sensitivity to radiation therapy based on their anatomic location.

Recent advances in the understanding of cancer have led to more personalized therapies, such as drugs that target particular proteins and tests that analyze gene expression patterns in tumors to predict a patient's response to therapy. This research, from the Moffitt Cancer Center in Tampa, Florida, brings a personalized approach to radiation treatment.

Researchers from Moffitt previously developed a radiation sensitivity index (RSI) that predicts how sensitive tumors are to radiation based on expression patterns of different genes. In a paper published in The International Journal of Radiation Oncology, Biology and Physics (2015; doi:10.1016/j.ijrobp.2015.06.021), they used the RSI to determine the radiation sensitivity of 704 metastatic and 1,362 primary colon tumors.

They discovered that metastatic colon tumors are more resistant to radiation than primary colon tumors. The researchers also report that radiation sensitivity may be dependent on the anatomic location of the tumor metastasis.

This study is one of the first to highlight the importance of the location of metastasis as well as the original primary tumor, in predicting response to radiation therapy. The researchers confirmed some of these findings by analyzing how effective radiation therapy was in 29 colon cancer tumors that metastasized to either the liver or lung. Their findings validated that those patients who had metastatic disease in their lungs had a better response to radiation then those who had metastatic disease in their liver, as predicted by RSI.

This study suggests that it may be possible to personalize radiation therapy for patients.

"Radiation sensitivity index provides the first opportunity to use tumor genetics to guide and optimize the radiation dose that patients receive. The consequences for this can be quite dramatic. We have estimated that up to 15% of patients will be candidates for dose optimization," explained senior study author Javier F. Torres-Roca, MD, director of Clinical Research and associate member of the Department of Radiation Oncology at Moffitt.

The medical community has noted these contributions to improving cancer care. According to a commentary in the International Journal of Radiation Oncology, Biology and Physics (doi:10.1016/j.ijrobp.2015.04.020), "Radiation sensitivity index is important progress towards personalizing radiation therapy. The results generate important hypotheses that could dramatically influence patient care."

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs